Skip to main content


ESMO 2019 Congress

September 28, 2019

The European Society of Medical Oncology (ESMO) annual congress was held September 26-30 in Barcelona, Spain.

Journal of Clinical Pathways was onsite to provide coverage of the most relevant and important sessions of the meeting.

Abemaciclib Plus Fulvestrant Improves OS in HR+/HER2- Breast Cancer

George W Sledge, MD, professor of medicine, Stanford University School of Medicine, shares overall survival results from the MONARCH 2 trial.

Watch Now


Selecting Quality Indicators to Improve Clinical Pathways

Aude Fourcade, researcher at Gustave Roussy, highlights an effort to to determine a definitive number of quality indicators and the importance of such indicators to assess and validate clinical pathways. 

Read More


Machine Learning Helps Prognosticate Patients With Breast Cancer

Yara Abdou, MD, details how a novel machine learning-assisted prognostication method based on genomic expression in the tumor microenvironment can further personalize breast cancer management. 

Read More


Can the ESMO Value Framework Contribute to Better Assessed Patient Quality of Life?

Andrew Bottomley, PhD, European Organization for Research and Treatment of Cancer, speaks to whether value frameworks such as the ESMO MCBS can contribute to higher patient quality of life and to the international standards for analyzing quality of life.

Read More


Neoadjuvant Combination Regimen Improves Outcomes in Triple-Negative Breast Cancer

A neoadjuvant combination regimen consisting of immunotherapy and chemotherapy provides greater anti-tumor activity than chemotherapy alone in patients with early-stage triple-negative breast cancer, according to new research. 

Read More


Evaluating PD-L1 Assays in Advanced Triple-Negative Breast Cancer

A post-hoc analysis of the IMpassion130 study evaluated the concordance of multiple PD-L1 immunohistochemistry assays and their ability to predict clinical activity in unresectable, advanced or metastatic triple-negative breast cancer. 

Read More


Significant Improvement in OS With CDK4/6 Inhibitor, Fulvestrant Combination in Women with HR+, HER2- Advanced Breast Cancer

A study presented at the ESMO Annual Congress showed that abemaciclib plus fluvestrant demonstrated a statistically significant improvement in overall survival in the Phase 3 MONARCH 2 clinical trial. 

Read More


Prognostic Factors After Stem Cell Transplant, Therapy for Hodgkin Lymphoma

Researchers analyzed the prognostic factors that influence outcomes after therapy in relapsed or refractory Hodgkin lymphoma. 

Read More


Addition of PARP Inhibitor to Front-Line Chemo, Maintenance in High-Grade Ovarian Cancer

The combination of a PARP inhibitor with front-line combination chemotherapy and continued PARP inhibitor maintenance significantly extends PFS in patients with newly diagnosed ovarian serous carcinoma, according to new research. 

Read More


AI Combining Radiomics, Clinical Data Predicts Response to Immunotherapy

A radiomics signature from a Spanish oncology institute combines radiomics and clinical data to predict response to immunotherapy with high specificity in patients with advanced solid tumors. 

Read More


Radiotherapy After Surgery Deemed Unnecessary for Patients With Prostate Cancer

Men with prostate cancer can be spared radiotherapy after surgery, according to presentations of the RADICALS-RT trial and a meta-analysis.

Read More


Meaningful Clinical Benefit Reported From First-Line Immunotherapy in Advanced HCC

A study showed “clinically meaningful improvements” in survival and response rates for first-line immunotherapy compared with standard-of-care therapy for advanced HCC.

Read More

Back to Top